Vicki L. Sato Sells 1,666 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 1,666 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $18.29, for a total transaction of $30,471.14. Following the transaction, the director now owns 118,043 shares in the company, valued at approximately $2,159,006.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Denali Therapeutics Price Performance

NASDAQ:DNLI opened at $16.00 on Friday. Denali Therapeutics Inc. has a 1-year low of $15.45 and a 1-year high of $33.31. The company has a 50-day moving average of $19.22 and a 200 day moving average of $19.23. The firm has a market cap of $2.23 billion, a PE ratio of -14.81 and a beta of 1.33.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.05). Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter in the previous year, the business earned ($0.75) earnings per share. Sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.62 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DNLI has been the topic of a number of analyst reports. HC Wainwright cut their price objective on shares of Denali Therapeutics from $105.00 to $95.00 and set a “buy” rating on the stock in a research report on Wednesday, February 28th. Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Denali Therapeutics in a report on Wednesday, February 28th. The Goldman Sachs Group cut their price target on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. Finally, UBS Group cut their price target on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, April 9th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Denali Therapeutics presently has a consensus rating of “Buy” and an average target price of $41.22.

Institutional Trading of Denali Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. CWM LLC lifted its position in shares of Denali Therapeutics by 216.7% during the fourth quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after buying an additional 1,376 shares during the last quarter. Assetmark Inc. lifted its position in shares of Denali Therapeutics by 49.1% during the third quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock valued at $44,000 after buying an additional 707 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Denali Therapeutics by 85.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,669 shares of the company’s stock valued at $46,000 after buying an additional 768 shares during the last quarter. KBC Group NV purchased a new stake in shares of Denali Therapeutics during the fourth quarter valued at about $53,000. Finally, Fisher Asset Management LLC purchased a new stake in shares of Denali Therapeutics during the fourth quarter valued at about $59,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.